Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. AMD
7. USO
8. AMC
9. META
10. NUAI

Go back to Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Gilead Sciences (NASDAQ: GILD) Delayed: 151.49 +1.38 (0.92%)
Previous Close $150.11    52 Week High $108.63 
Open $150.11    52 Week Low $71.39 
Day High $151.92    P/E 83.70 
Day Low $148.22    EPS $1.81 
Volume 2,492,812